# Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI

> **NCT01140321** · PHASE2 · COMPLETED · sponsor: **Ente Ospedaliero Ospedali Galliera** · enrollment: 120 (actual)

## Conditions studied

- Osteoporosis
- Thalassemia Major
- Thalassemia Intermedia

## Interventions

- **DRUG:** Neridronate

## Key facts

- **NCT ID:** NCT01140321
- **Lead sponsor:** Ente Ospedaliero Ospedali Galliera
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01140321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01140321, "Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01140321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*